Advertisement

Topics

Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study

10:32 EST 10 Nov 2017 | Speciality Pharma Journal

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data for BLU-285, a potent and highly selective KIT and PDGFRα inhibitor in development as a potential treatment for patients with advanced …

Original Article: Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study

NEXT ARTICLE

More From BioPortfolio on "Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study"

Advertisement
Quick Search
Advertisement
Advertisement